Lohne

This research aims to evaluate the long-term safety and tolerability of pelacarsen (TQJ230) in adults with established cardiovascular disease and elevated Lipoprotein(a) who have completed the parent trial CTQJ230A12301. The study is an open-label extension following the phase 3 parent study, providing participants continued access to pelacarsen after the initial trial. Participants will receive pelacarsen 80 mg by subcutaneous injection once a month during this open-label extension. The study is single-arm and multicenter, focusing on continued treatment with pelacarsen for up to 36 months after completion of the parent study. Throughout the study, participants will be monitored regularly to assess safety and tolerability, with particular attention to adverse events occurring up to 36 months. Researchers will collect data on health status throughout this period to understand the long-term effects of pelacarsen in this patient population.

Researchers are evaluating the effectiveness and safety of oral minoxidil 1 mg in treating women with androgenetic alopecia, a type of hormone-related hair loss. This phase III, multi-center, randomized, double-blind clinical trial compares oral minoxidil 1 mg to a 2% minoxidil topical solution and placebo. Approximately 520 adult female patients with hair thinning in the centroparietal scalp area will participate across 20 centers in Germany, Spain, Italy, and Portugal. Participants will be randomly assigned in a 2:2:1 ratio to one of three groups: oral minoxidil 1 mg plus topical vehicle solution, oral placebo plus topical 2% minoxidil solution, or oral placebo plus topical vehicle solution. Treatments involve taking one tablet daily (preferably in the evening) and applying 1 ml of topical solution twice daily for six months. The study includes a screening period of up to 8 weeks, a 24-week treatment period, and a 4-week follow-up. During the trial, participants will visit the clinical center five times and receive two phone calls for safety monitoring. Assessments include hair density photos, scalp hair growth evaluations, vital signs, physical exams, blood and urine tests, ECGs, and hypertrichosis evaluations. Women of childbearing potential will have pregnancy tests. Daily electronic diaries will track treatment adherence and side effects. The main outcome measured is the change in non-vellus hair counts from baseline to week 24.